精元康胶囊联合化疗治疗晚期非小细胞肺癌临床研究  

The Clinical Research of Jing Yuan Kang Capsule Combined Chemotherapy on Advanced Stage Nonsmall-cell Lung Cancer

作　　者：蒋士卿[1,2] 王红玲[2] 

机构地区：[1]南京中医药大学,江苏南京210029 [2]河南中医学院,河南郑州450008

出　　处：《中医学报》2010年第3期385-386,共2页Acta Chinese Medicine

基　　金：国家十五科技攻关艾滋病专项课题(编号:2004BA719A09-0203)

摘　　要：目的:观察精元康胶囊对非小细胞肺癌(NSCLC)应用GP方案化疗的影响。方法:62例小细胞肺癌患者均采用GP方案化疗,其中治疗组32例化疗前3d开始至化疗结束后14d加用精元康胶囊,对照组32例单用化疗,比较两组近期疗效、化疗后生活质量评价、血液毒性反应情况,并进行相关数据对比分析。结果:两组病例近期疗效比较治疗组与对照组相似(P>0.05)。化疗后患者生活质量评价治疗组优于对照组(P<0.05)。治疗组化疗后血液毒性反应明显低于对照组,差异有显著性(P<0.05)。结论:精元康胶囊联合化疗治疗晚期非小细胞肺癌能改善患者临床症状、提高患者生活质量、减轻化疗后骨髓抑制。Objective：To observe effect of Jing Yuan Kang Capsule to NSCLC that made use of GP schema. Methods：62 cases were adopted GP schema chemotherapy,32 cases in treatment team was adopted chemotherapy,from the first 3 days to the end of the chemotherapy and in 14 days,add to Jing Yuan Kang capsule,32 cases in control team only was adopted chemotherapy to compare curative effect in the near future,quality of life evaluation after chemotherapy and hematotoxicity reaction in two teams and to carry out correlated data contrast analysis. Results：Comparing to curative effect in the near future of two group,it is similar（ P 0. 05） ,quality of life evaluation of treatment team is better than it of control team,hematotoxicity reaction of treatment is lower than it of control group,contrast is notable（ P 0. 05）. Conclusion：Jing Yuan Kang capsule with chemotherapy on advanced stage NSCLC can improve patient clinical symptom,boost patient quality of life and ease BMD after chemotherapy.

关 键 词：非小细胞肺癌 精元康胶囊 骨髓抑制 吉西他滨 顺铂 

分 类 号：R273.9[医药卫生—中西医结合]